Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, Dimopoulos MA, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N, Maniatis A. Zervas K, et al. Among authors: pouli a. Eur J Haematol. 2001 Jan;66(1):18-23. doi: 10.1034/j.1600-0609.2001.00285.x. Eur J Haematol. 2001. PMID: 11168503 Clinical Trial.
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C, Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou N, Tzilianos M, Chatzivassili A, Kyrtsonis MC, Panayiotidis P, Maniatis A; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: pouli a. Ann Oncol. 2003 Jul;14(7):1039-44. doi: 10.1093/annonc/mdg287. Ann Oncol. 2003. PMID: 12853344 Free article. Clinical Trial.
Multiple myeloma in elderly patients: prognostic factors and outcome.
Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P, Grigoraki V, Anagnostopoulos N, Economopoulos T, Maniatis A, Dimopoulos MA. Anagnostopoulos A, et al. Among authors: pouli a. Eur J Haematol. 2005 Nov;75(5):370-5. doi: 10.1111/j.1600-0609.2005.00532.x. Eur J Haematol. 2005. PMID: 16191085
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Terpos E, et al. Among authors: pouli a. Br J Haematol. 2006 Dec;135(5):688-92. doi: 10.1111/j.1365-2141.2006.06356.x. Br J Haematol. 2006. PMID: 17107351 Free article.
Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.
Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopoulos T, Zervas K, Dimopoulos MA; Greek Myeloma Study Group. Eleutherakis-Papaiakovou V, et al. Among authors: pouli a. Leuk Lymphoma. 2007 Feb;48(2):337-41. doi: 10.1080/10428190601126602. Leuk Lymphoma. 2007. PMID: 17325894
68 results